DDInter1059 DDInter105
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Levomilnacipran {u} (Compound) resembles {v} (Compound) Milnacipran
Levomilnacipran {u} (Compound) binds {v} (Gene) CYP2C19
Levomilnacipran {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin Uptake Inhibitors
Levomilnacipran {u} (Compound) downregulates {v} (Gene) GJA1
Levomilnacipran {u} (Compound) causes {v} (Side Effect) Infection
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Levomilnacipran {u} may lead to a major life threatening interaction when taken with {v} Doxepin
Levomilnacipran {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Iobenguane
Levomilnacipran (Compound) resembles Milnacipran (Compound)
Levomilnacipran (Compound) binds CYP2C19 (Gene)
Levomilnacipran (Compound) is included by Serotonin Uptake Inhibitors (Pharmacologic Class)
Levomilnacipran (Compound) downregulates GJA1 (Gene)
Levomilnacipran (Compound) causes Infection (Side Effect)
Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Levomilnacipran may lead to a major life threatening interaction when taken with Doxepin
Levomilnacipran may lead to a major life threatening interaction when taken with Methylene blue
Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Levomilnacipran may lead to a major life threatening interaction when taken with Iobenguane